Tirzepatide, sold as Mounjaro, is also primarily a diabetes treatment
Patients frequently report clearer photos, defined cheekbones, and a slimmer jawline
Retatrutide (LY3437943) targets GIP, GLP-1, and glucagon receptors simultaneously a mechanism that produced up to 24.2% body weight reduction in Phase 2 trials
Lauren Levy, a board-certified dermatologist who specializes in both dermatology and obesity medicine, reports that approximately 55% of her patients on GLP-1 medications experience hair loss or changes in hair texturesignificantly higher than the clinical trial data suggests
It also boosts the performance of other antioxidants, including CoQ10, vitamins C and E, and alpha lipoic acid